Aptinyx Inc. (APTX)
After hours:
| Previous close | 0.5826 |
| Open | 0.5800 |
| Bid | 0.5510 x 4000 |
| Ask | 0.5700 x 1800 |
| Day's range | 0.5514 - 0.5900 |
| 52-week range | 0.5514 - 4.7300 |
| Volume | |
| Avg. volume | 457,434 |
| Market cap | 38.259M |
| Beta (5Y monthly) | 1.46 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Aptinyx to Participate in H.C. Wainwright Global Investment Conference
EVANSTON, Ill., May 18, 2022--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that company management will present at the H.C. Wainwright Global Investment Conference to be held May 23-26, 2022. The presentation will be available on-demand through the H.C. Wainwright conference portal, beginning at 7:00 AM ET on Tuesday, May 24, 2022.
- Business Wire
Aptinyx Announces Poster Presentation Highlighting Preclinical Data on NYX-783 in Models of PTSD at the 2022 American Psychiatric Association Annual Meeting
EVANSTON, Ill., May 17, 2022--Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that data from preclinical studies of NYX-783 in models of post-traumatic stress disorder (PTSD) will be presented in a poster at the American Psychiatric Association Annual Meeting being held May 21 – 25, 2022 in New Orleans, LA.
- Business Wire
Aptinyx Reports First Quarter 2022 Financial Results and Highlights Recent Clinical Progress
EVANSTON, Ill., May 12, 2022--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today reported financial results for the first quarter of 2022 and highlighted recent progress across the company’s pipeline of novel, clinical-stage, NMDA receptor modulators.
